— Know what they know.
Not Investment Advice

ENLV

Enlivex Therapeutics Ltd.
1W: -1.9% 1M: -2.9% 3M: +22.3% YTD: +35.1% 1Y: -8.9% 3Y: -71.6% 5Y: -92.8%
$1.02
-0.06 (-5.56%)
After Hours: $1.12 (+0.10, +9.80%)
NASDAQ · Healthcare · Biotechnology · $24.8M · Alpha Radar Sell · Power 38
Smart Money Score
Moderate 50
Insider
Congress
ETF Holdings
Key Statistics
Market Cap$24.8M
52W Range0.66-2.1
Volume223,353
Avg Volume358,394
Beta1.64
Dividend
Analyst Ratings
3 Buy 1 Hold 0 Sell
Consensus Buy
Company Info
CEOOren Hershkovitz
Employees71
SectorHealthcare
IndustryBiotechnology
IPO Date2014-07-31
14 Einstein Street
Ness Ziona 7403618
IL
972 8 662 3301
About Enlivex Therapeutics Ltd.

Enlivex Therapeutics Ltd. operates as a clinical-stage macrophage reprogramming immunotherapy company. It is developing Allocetra, a cell-based therapy to treat organ dysfunction and failure associated with sepsis that is in phase II clinical trial, as well as in preclinical trial to treat solid tumors. Enlivex Therapeutics Ltd. was founded in 2005 and is headquartered in Nes Ziona, Israel.

Recent Insider Trades

NameTypeSharesPriceDate
Murray Michael Antho S-Sale 56,390 $2.78 2015-10-09
WEATHERSON HARVEY D A-Award 12,000 $1.25 2008-01-02
RANEY DENNIS R A-Award 12,000 $1.25 2008-01-02

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms